Schmäh Juliane, Fedders Birthe, Panzer-Grümayer Renate, Fischer Susanna, Zimmermann Martin, Dagdan Elif, Bens Susanne, Schewe Denis, Moericke Anja, Alten Julia, Bleckmann Kirsten, Siebert Reiner, Schrappe Martin, Stanulla Martin, Cario Gunnar
Department of Pediatrics, University Medical Center Schleswig-Holstein, Kiel, Germany.
Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.
Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26539. Epub 2017 Apr 1.
A high-level expression of the CRLF2 gene is frequent in precursor B-cell acute lymphoblastic leukemia (pB-ALL) and can be caused by different genetic aberrations. The presence of the most frequent alteration, the P2RY8/CRLF2 fusion, was shown to be associated with a high relapse incidence in children treated according to ALL-Berlin-Frankfurt-Münster (BFM) protocols, which is poorly understood. Moreover, the frequency of other alterations has not been systematically analyzed yet.
CRLF2 mRNA expression and potential genetic aberrations causing a CRLF2 high expression were prospectively assessed in 1,105 patients treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)-BFM ALL 2009 protocol. Additionally, we determined copy number alterations in selected B-cell differentiation genes for all CRLF2 high-expressing pB-ALL cases, as well as JAK2 and CRLF2 mutations.
A CRLF2 high expression was detected in 26/178 (15%) T-cell acute lymphoblastic leukemia (T-ALL) cases, 21 of them (81%) had been stratified as high-risk patients by treatment response. In pB-ALL, a CRLF2 high expression was determined in 91/927 (10%) cases; the P2RY8/CRLF2 rearrangement in 44/91 (48%) of them, supernumerary copies of CRLF2 in 18/91 (20%), and, notably, the IGH/CRLF2 translocation was detected in 16/91 (18%). Remarkably, 7 of 16 (44%) patients with IGH/CRLF2 translocation had already relapsed. P2RY8/CRLF2- and IGH/CRLF2-positive samples (70 and 94%, respectively) were characterized by a high frequency of additional deletions in B-cell differentiation genes such as IKZF1 or PAX5.
Our data suggest that this high frequency of genetic aberrations in the context of a high CRLF2 expression could contribute to the high risk of relapse in P2RY8/CRLF2- and IGH/CRLF2-positive ALL.
CRLF2基因的高表达在B淋巴细胞前体急性淋巴细胞白血病(pB-ALL)中很常见,并且可能由不同的基因畸变引起。最常见的改变,即P2RY8/CRLF2融合的存在,已被证明与按照柏林-法兰克福-明斯特(BFM)方案治疗的儿童高复发率相关,对此了解甚少。此外,其他改变的频率尚未得到系统分析。
在按照意大利儿科血液肿瘤协会(AIEOP)-BFM ALL 2009方案治疗的1105例患者中,前瞻性评估CRLF2 mRNA表达以及导致CRLF2高表达的潜在基因畸变。此外,我们确定了所有CRLF2高表达的pB-ALL病例中选定B细胞分化基因的拷贝数改变,以及JAK2和CRLF2突变。
在26/178(15%)的T淋巴细胞急性淋巴细胞白血病(T-ALL)病例中检测到CRLF2高表达,其中21例(81%)根据治疗反应被分层为高危患者。在pB-ALL中,91/927(10%)的病例中检测到CRLF2高表达;其中44/91(48%)存在P2RY8/CRLF2重排,18/91(20%)存在CRLF2的额外拷贝,值得注意的是,在16/91(18%)中检测到IGH/CRLF2易位。值得注意的是,16例IGH/CRLF2易位患者中有7例(44%)已经复发。P2RY8/CRLF2和IGH/CRLF2阳性样本(分别为70%和94%)的特征是B细胞分化基因如IKZF1或PAX5中额外缺失的频率较高。
我们的数据表明,在CRLF2高表达情况下这种高频率的基因畸变可能导致P2RY8/CRLF2和IGH/CRLF2阳性ALL的高复发风险。